DK154073B - 9-fluor-prostaglandinderivater - Google Patents
9-fluor-prostaglandinderivater Download PDFInfo
- Publication number
- DK154073B DK154073B DK294382A DK294382A DK154073B DK 154073 B DK154073 B DK 154073B DK 294382 A DK294382 A DK 294382A DK 294382 A DK294382 A DK 294382A DK 154073 B DK154073 B DK 154073B
- Authority
- DK
- Denmark
- Prior art keywords
- group
- residue
- alkyl
- hydrogen
- direct bond
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
- -1 hydroxymethylene group Chemical class 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 7
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- RRUPOVMZBGWSMY-ABZYKWASSA-N (2r,3s)-1-fluoro-2-heptyl-3-octylcyclopentane Chemical class CCCCCCCC[C@H]1CCC(F)[C@@H]1CCCCCCC RRUPOVMZBGWSMY-ABZYKWASSA-N 0.000 abstract description 2
- 239000004015 abortifacient agent Substances 0.000 abstract description 2
- 231100000641 abortifacient agent Toxicity 0.000 abstract description 2
- 230000003529 luteolytic effect Effects 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 15
- 150000003180 prostaglandins Chemical class 0.000 description 12
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Description
i
DK 154073 B
Opfindelsen angår hidtil ukendte 9-fluor-prostaglandinderiva-ter, der har svangerskabsforebyggende eller abortfremkaldende virkning.
5 Fra den meget omfattende tekniske viden om prostaglandiner og deres analoge ved man, at denne stofklasse på grund af dens biologiske og farmakologiske egenskaber er egnet til behandling af pattedyr, herunder mennesket. Dens anvendelse støder dog ofte på vanskeligheder. De fleste naturlige prostaglandi-10 ner har en til terapeutiske formål for kort varighed af virkningen, da de hurtigt nedbrydes metabolisk af forskellige enzymatiske processer. Alle strukturforandringer har det mål at forøge både varigheden af virkningen og selektiviteten af virkningen.
15 9-desoxy-9-halogen-prostaglandinderivater er kendt. Således beskriver f.eks. EP offentliggørelsesskrift nr. 30377 9-chlor-derivater.
20 Fra tysk offentliggørelsesskrift nr. 2.628.364 samt publikationerne af C.E. Arroniz m.fl. i Prostaglandins .16, s. 47 (1978) og J. N. Muchowski i Chemistry, Biochemistry and Pharmacological Activity of Prostanoids (Pergamon Press 1978, s.
39) kendes også prostaglandinderivater med et fluoratom i 9-25 stilling.
De i sidstnævnte offentliggørelsesskrift omtalte forbindelser indeholder som eneste strukturvariant til prostaglandinernes naturlige sidekæde en alkylgruppe i 15-stilling.
30
Det har nu vist sig, at ved andre strukturændringer i den nedre sidekæde og eventuelt i 1-stillingen i 9-fluor-prostaglan-diner kan der opnås en længere varighed af virkningen, en større selektivitet og en bedre virkning. Den fra ovennævnte 35 litteratursteder kendte forbindelse 9/i-f luor-lla, 15a-dihy- droxy-5-cis-13-trans-prostadiensyre er således abortivt inaktiv i en dosis på 0,3 mg/dag, medens forbindelserne ifølge opfindelsen er aktive i en lavere dosis.
2
DK 154073 B
Opfindelsen angår 9-fluor-prostaglandinderivater med den almene formel I
F
5 \-(i) Y D - E - R5
= OH
OH
io hvor 9-F-atomet og 15-OH-gruppen uafhængigt er a- eller β-stillede, og 15 .0 . ^
Ri er -C-OR2, hvor R2 betyder et hydrogenatom eller en al- kylgruppe med 1-4 C-atomer 20 eller Rj er resten -C-NHR3, hvor R3 betyder en Ci_io~alkano- yl- eller methan- eller isopropansulfonylrest eller resten R2, og A er en - CH2-CH2 eller en cis-CH=CH-gruppe, 25 B er en -CH2-CH2- eller en trans-CH=CH- eller en -CaC-gruppe, 0 og E tilsammen er en direkte binding, eller 30 D er en ligekædet eller forgrenet alkylengruppe med 1-10 C-atomer, E er et oxygenatom, en direkte binding, en -CeC-gruppe eller en -CR6=CR7-gruppe, ider R6 og R7 er forskellige og betyder et 35 hydrogenatom eller en methylgruppe, R5 er et hydrogenatom, en ligekædet eller forgrenet, mættet eller umættet alkylgruppe med 1-6 C-atomer eller, når E bety-
DK 154073 B
3 der et oxygenatom, en phenylgruppe, idet gruppen -DER5 ikke er resten n-pentyl, og hvis R2 betyder et hydrogenatom, deres salte med fysiologisk anvendelige baser.
5 Fluoratomet i 9-stilling i formlen I kan være både a- og flet 11 let.
Som alkylgrupper R2 er der tale om ligekædede eller forgrenede alkylgrupper med 1-4 C-atomer, som f.eks. methyl, ethyl, 10 propyl, butyl, isobutyl og tert.-butyl.
Som alkylgrupper R5 er der tale om ligekædede og forgrenede mættede og umættede alkylrester med 1-6 C-atomer. Eksempelvis skal nævnes methyl-, ethyl-, propyl-, butyl-, isobutyl-, 15 tert.-butyl, pentyl-, hexyl-, butenyl, isobutenyl-, propenyl-og pentenyIgruppen.
Når E er et oxygenatom, kan R5 også være en phenylgruppe.
20 Som alkylengrupper D er der tale om ligekædede eller forgrenede mættede og umættede alkylenrester, fortrinsvis mættede, med 1-10, især 1-5 C-atomer. Som eksempler skal nævnes: Nethylen, ethylen, 1,2-propylen, ethylethylen, trimethylen, tetramethy-len, pentamethylen, 1-methyltetramethylen, 1-methyltrimethy-25 len, 1-methylenethylen, 1-methylentetramethylen.
Til saltdannelse egner sig uorganiske og organiske baser, der er velkendt for fagmanden til dannelse af fysiologisk anvendelige salte. Eksempelvis skal nævnes alkalihydroxider såsom 30 natrium- og kaliumhydroxid, jordalkalihydroxider såsom calciumhydroxid, ammoniak, aminer såsom ethanolamin, diethanolamin, triethanolamin, N-methylglucamin, morpholin og tris-(hydroxymethyl )-methyl ami η.
35 Sammenlignet med PQE-deri vater udmærker de hidtil ukendte 9-f 1 uor-prostaglandiner sig ved større stabilitet.
De hidtil ukendte 9-fluor-prostanderivater af den almene formel I er værdifulde farmaka, da de med lignende virkningsspek-
DK 154073B
4 trum udviser en væsentligt forbedret (højere specificet) og især væsentligt længerevarende virkning end de tilsvarende naturlige prostaglandiner.
5 De hidtil ukendte prostaglandinanaloge virker stærkt luteoly-tisk, dvs. at til udløsning af en luteolyse behøver man væsentligt ringere doseringer end med de tilsvarende naturlige prost ag1 and i ne r.
10 Også til udløsning af aborter, især efter oral eller intrava-ginal applikation, kræves der væsentligt ringere mængder af de hidtil ukendte prostaglandinanaloge sammenlignet med de naturlige prostaglandiner.
15 Ved registrering af den isotoniske uteruskontraktion på narkotiseret rotte og på isoleret rotte-uterus viser det sig, at stofferne ifølge opfindelsen er væsentlige mere virksomme, og at deres virkning varer længere end virkningen af de naturlige prostaglandiner.
20
De hidtil ukendte prostaglandinderivater er egnede til efter en enkelt enteral eller parenteral applikation at inducere en menstruation eller at afbryde et svangerskab. De egner sig endvidere til synkronisering af seksualcyklen hos hunpattedyr 25 såsom kanin, okse, hest, svin etc.
Den gode vævsspecificitet af de antifertilt virksomme stoffer ifølge opfindelsen viser sig ved undersøgelse på andre glat-muskulære organer, såsom på marsvine-ileum eller på isoleret 30 kanin-trachea, hvor der iagttages en væsentligt ringere stimulering end med de naturlige prostaglandiner.
De virksomme stoffer ifølge opfindelsen skal i forbindelse med de i galenikken kendte og sædvanlige hjælpestoffer tjene til 35 fremstilling af præparater til udløsning af en abort eller til cyklusstyring. Til dette formål kan præparaterne indeholde 0,01-50 mg af den aktive forbindelse.
5
DK 154073B
Det følgende eksempel illustrerer fremstillingen af en forbindelse ifølge opfindelsen.
EKSEMPEL
5 (5Z,13E)-(9R,11R,15R)-11,15-dihydroxy-9-f1uor-16-phenoxy-17,18, 19,20-tetranor-5,13-prostadiensyrernethyl ester.
Til en opløsning af 5,7 g (5Z,13E)-(9S,llR,15R)-9-hydroxy-ll, 10 15-bis-(tetrahydropyran-2-yloxy)-16-phenoxy-17,18,19,20-tetra nor-5, 13-prostadiensyremethylester (fremstillet af den tilsvarende syre ved omsætning i methylenchlorid med 0,5 molær ethe-risk diazomethanopløsning ved 0°C) i 18 ml pyridin sætter man ved 00C 3,8 g p-toluolsulfonsyrechlorid, omrører i 16 timer 15 ved isbadtemperatur og 48 timer ved stuetemperatur. Derefter tilsætter man 15 ml vand, omrører i 3 timer ved 20eC, fortynder med ether, ryster efter hinanden med vand, 5%-ig svovlsyre, 5%-ig natriumbicarbonatopløsning og vand. Man tørrer den organiske fase over magniumsulfat og inddamper i vakuum. Efter 20 kromatografi af remanensen på kiselgel får man med hexan/eddi-keester (3+2) 5,2 g af 9-tosylatet som en farveløs olie.
IR: 2950, 2875, 1733, 1600, 1590, 1496, 1365, 1240, 974/cm.
25 Til en opløsning af 5,2 g af det i det foregående fremkomne 9-tosylat i 75 ml absolut dimethylsulfoxid sætter man 13 g te-trabutylammoniumfluorid (tørret ved flere ganges inddampning med toluol) og omrører opløsningen i 1% time ved 22°C under argon. Derefter fortynder man med ether, ryster fire gange med 30 vand, tørrer den organiske fase over magniumsulfat og inddamper i vakuum. Remanensen renser man ved kromatografi på kiselgel. Med hexan/eddikeester (9+1) som elueringsmiddel får man først den tilsvarende å8*9-forbindelse, og som polær komponent 0,72 g (5Z,13E)-(9R,llR,15R)-ll,15-bis-(tetrahydropyran-2-yl-35 oxy)-9-fluor-16-phenoxy-17,18,19,20-tetranor-5,13-prostadiensyremethylester som en farveløs olie.
IR: 2955, 1733, 1600, 1588, 1495, 970/cm.
DK 154073 B
6
Ned henblik på fraspaltning af beskyttelsesgrupper omrører man 0,72 g af den i det foregående fremkomne 9|8-f luorforbindelse i 16 timer ved 22°C med 20 ml af en blanding af eddikesyre, vand og tetrahydrofuran (65+35+10) og inddamper derefter i va-5 kuum. Remanensen renser man ved kromatografi på kiselgel. Ned ether som elueringsmiddel får man 370 mg af titelforbindelsen som en farveløs olie.
IR: 3600, 3430 (bred), 2952, 2930, 2870, 1730, 1600, 1588, 10 1495, 970/cm.
Virkningen af forbindelserne ifølge opfindelsen sammenlignet med den fra Prostaglandins .16, s. 47 (1978) og tysk offentliggørelsesskrift nr. 2.628.364 kendte forbindelse 9/S-fluor-lla, 15 l5a-dihydroxy-5-cis-13-trans-prostadiensyre fremgår af følgende tabel, der viser resultaterne af et forsøg med marsvinegra-viditet (behandling d. 43. og 44. dag i graviditeten med applikation ved subkutan injektion 1 x /dag og iagttagelse til 50. dag, hvor dyrene blev drrnbt og undersøgt). Forbindelse 1 i 20 tabellen er den kendte forbindelse, og forbindelserne 2-11 er ifølge opfindelsen. Oet vil ses, at den kendte forbindelse var inaktiv i en dosis på 0,3 mg/dag, medens forbindelserne ifølge opfindelsen var aktive i en lavere dosis.
25 30 35 7 UK 154073 Β
Tabel iabort-rate
Forbindelse_ .Dosis, mg/dag_^(marsvin, subkut 1. f 0,3 00/3
OH OH
2. 0,03 3/3
F
1 V yv
—/ \/ \ COOH
V\yvX^v'
OH OH
3 . 0,03 3/3
F
\---o\ _ /\/\ COOH
V'V/vXy—\
OH OH
4. F 0,1 3/3
OH ' OH
5. F 0,03 .3/10 OH OH N ' 6· F',_•'VN/N/'”™ 0,1 3/3 ·
OH OH
F
7 V. COOH g 3 3/3 z^'N^N/N/ ( 0,1 2/3 8
Tabel (fortsat) D&ol§4fi|3B
Forbindelse___:·_ Dosis 'mg/daÆ_ η r gnhVnf^; - 8. F 0,1 3/3 /^|N\==y/\/\ C00CH3 OH OH N /.
9. F 0,3 4/6 ^WV\ conhso2ch3
OH OH
10. 0,1 3/3
F
/^γ\==/\/\ conh2 vA^o_^ .. OH OH λ--' 11. p 0,1 3/3
OH OH
Claims (2)
- 32K 154073B Patentkrav. 9-flajorprostaglandindenivater med den almene f ormeil I 5 F [-f'' (I) n/\b ν' D - E - R_ = OH 5 10 - OH hvor
- 9-F-atomet og 15-OH-gruppen uafhængigt er a- eller jp-stiIlede, 15 og Ri er -C-OR2, hvor Itø betyder et hydrogenatfeom eller en al- kylgrqppe med 1-4 C-atomer, eller Ri er 20 resten -C——NHR3, hvor % betyder en Ci_io-allGanqyl- eller æe-than- eller isopropansulfonylrest eller resten R2,» oog A er em -CH2-CH2- eller an cis-CH=CH-gruppe, 25. er em -CH2-CH2- eller ©m trans-CH=CH- eller en -CD*C-gruppe, D og E tilsammen er en direkte binding, eller D er en ligekædet eller forgrenet alkylengruppe mod 1-10 C-a-30 tomer, E er et oxygenatom, en direkte binding, en -CEC-fgr.uppe eller en -CRg=CR7-gruppe, idet ;Rg og R7 er forskellige qg betyder et hydrogenatom, eller en methylgruppe, R5 er et hydrogenatom, en ligekædet eller forgirenet, mættet eller umættet alkylgruppe med 1-6 C-atomer eller,, når E betyder et oxygenatom, en phenylgruppe, idet gruppen —DER5 ikke er 35 DK 154073 B resten n-pentyl, og hvis F?2 betyder et hydrogenatom, deres salte med fysiologisk anvendelige baser. 5 15 20 25 30 35
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813126924 DE3126924A1 (de) | 1981-07-03 | 1981-07-03 | 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
| DE3126924 | 1981-07-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK294382A DK294382A (da) | 1983-01-04 |
| DK154073B true DK154073B (da) | 1988-10-10 |
| DK154073C DK154073C (da) | 1989-02-27 |
Family
ID=6136403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK294382A DK154073C (da) | 1981-07-03 | 1982-06-30 | 9-fluor-prostaglandinderivater |
| DK123587A DK123587D0 (da) | 1981-07-03 | 1987-03-10 | Analogifremgangsmaade til fremstilling af 9-fluor-prostaglandinderivater |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK123587A DK123587D0 (da) | 1981-07-03 | 1987-03-10 | Analogifremgangsmaade til fremstilling af 9-fluor-prostaglandinderivater |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4454339A (da) |
| EP (1) | EP0069696B1 (da) |
| JP (1) | JPS588059A (da) |
| AT (1) | ATE17475T1 (da) |
| AU (1) | AU559449B2 (da) |
| CA (1) | CA1218060A (da) |
| CS (1) | CS236484B2 (da) |
| DE (2) | DE3126924A1 (da) |
| DK (2) | DK154073C (da) |
| ES (1) | ES513645A0 (da) |
| HU (1) | HU190692B (da) |
| IE (1) | IE53907B1 (da) |
| IL (1) | IL66165A (da) |
| SU (1) | SU1301308A3 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822909A (en) * | 1983-06-10 | 1989-04-18 | Asashi Glass Company Ltd. | 7-fluoroprostaglandins and process for their production |
| DE3325175A1 (de) * | 1983-07-08 | 1985-01-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11-halogen-prostanderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4549980A (en) * | 1983-10-11 | 1985-10-29 | Mobay Chemical Corporation | White modification of a bis-triazinyl amino stilbene optical brightener and a process for making the same |
| DE3347128A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3504044A1 (de) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel |
| DE3510978A1 (de) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| US5891910A (en) * | 1987-07-17 | 1999-04-06 | Schering Aktiengesellschaft | 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents |
| JP2716986B2 (ja) * | 1987-07-17 | 1998-02-18 | シエーリング アクチエンゲゼルシヤフト | ９‐ハロゲン‐（ｚ）‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用 |
| AU624078B2 (en) * | 1987-07-17 | 1992-06-04 | Schering Aktiengesellschaft Berlin Und Bergkamen | 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs |
| DE3831222A1 (de) * | 1988-09-09 | 1990-03-22 | Schering Ag | 6-oxo-9-fluor-prostaglandin-derivate verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| DE3923797A1 (de) * | 1989-07-14 | 1991-01-24 | Schering Ag | 9-fluor-prostaglandin-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| DE4024347A1 (de) * | 1990-07-27 | 1992-01-30 | Schering Ag | Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| US5385945A (en) * | 1992-10-21 | 1995-01-31 | Allergan, Inc. | 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
| US5721273A (en) * | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
| US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| EP1005336A4 (en) | 1997-07-09 | 2001-01-17 | Androsolutions Inc | IMPROVED METHODS AND COMPOSITIONS FOR TREATING MALE ERECTIONAL DISORDERS |
| US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| CA2306837C (en) | 1997-10-28 | 2007-05-08 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| US20040266880A1 (en) * | 2002-02-22 | 2004-12-30 | Fumie Sato | Antipruritics |
| US7737182B2 (en) * | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
| CA2465103C (en) | 2002-08-09 | 2011-04-26 | Taisho Pharmaceutical Co., Ltd. | Use of a prostaglandin derivative as an anti-pruritic agent |
| JP4477504B2 (ja) * | 2002-11-13 | 2010-06-09 | 大正製薬株式会社 | 鎮痒剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3997587A (en) * | 1975-06-26 | 1976-12-14 | Syntex (U.S.A.) Inc. | D1- and 8R-9-fluoro-prostadienoic acid derivatives |
| DE2950027A1 (de) * | 1979-12-10 | 1981-06-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
-
1981
- 1981-07-03 DE DE19813126924 patent/DE3126924A1/de not_active Withdrawn
-
1982
- 1982-06-23 CA CA000405837A patent/CA1218060A/en not_active Expired
- 1982-06-24 SU SU823456800A patent/SU1301308A3/ru active
- 1982-06-24 JP JP57107696A patent/JPS588059A/ja active Granted
- 1982-06-25 DE DE8282730087T patent/DE3268528D1/de not_active Expired
- 1982-06-25 AT AT82730087T patent/ATE17475T1/de active
- 1982-06-25 EP EP82730087A patent/EP0069696B1/de not_active Expired
- 1982-06-29 IL IL66165A patent/IL66165A/xx unknown
- 1982-06-29 CS CS824906A patent/CS236484B2/cs unknown
- 1982-06-30 DK DK294382A patent/DK154073C/da not_active IP Right Cessation
- 1982-07-01 AU AU85528/82A patent/AU559449B2/en not_active Ceased
- 1982-07-01 ES ES513645A patent/ES513645A0/es active Granted
- 1982-07-02 HU HU822185A patent/HU190692B/hu unknown
- 1982-07-02 IE IE1611/82A patent/IE53907B1/en unknown
- 1982-07-06 US US06/395,448 patent/US4454339A/en not_active Expired - Fee Related
-
1987
- 1987-01-20 US US07/004,733 patent/US4789685A/en not_active Expired - Fee Related
- 1987-03-10 DK DK123587A patent/DK123587D0/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL66165A0 (en) | 1982-09-30 |
| HU190692B (en) | 1986-10-28 |
| DK123587A (da) | 1987-03-10 |
| AU559449B2 (en) | 1987-03-12 |
| ES8304078A1 (es) | 1983-03-16 |
| ATE17475T1 (de) | 1986-02-15 |
| AU8552882A (en) | 1983-01-06 |
| EP0069696B1 (de) | 1986-01-15 |
| IE53907B1 (en) | 1989-04-12 |
| IL66165A (en) | 1986-01-31 |
| CA1218060A (en) | 1987-02-17 |
| EP0069696A2 (de) | 1983-01-12 |
| EP0069696A3 (en) | 1983-03-16 |
| CS236484B2 (en) | 1985-05-15 |
| US4454339A (en) | 1984-06-12 |
| ES513645A0 (es) | 1983-03-16 |
| IE821611L (en) | 1983-01-03 |
| SU1301308A3 (ru) | 1987-03-30 |
| JPS588059A (ja) | 1983-01-18 |
| US4789685A (en) | 1988-12-06 |
| DE3268528D1 (en) | 1986-02-27 |
| DK154073C (da) | 1989-02-27 |
| DE3126924A1 (de) | 1983-01-20 |
| JPH0443906B2 (da) | 1992-07-20 |
| DK294382A (da) | 1983-01-04 |
| DK123587D0 (da) | 1987-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK154073B (da) | 9-fluor-prostaglandinderivater | |
| DK170889B1 (da) | 9-halogen-prostanderivater og lægemidler indeholdende dem | |
| EP0030377B1 (de) | 9-Chlor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel | |
| US4699920A (en) | 9-halo-2-prostaglandin derivatives, processes for the preparation thereof and use thereof as medicinal agents | |
| NO155537B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive, nye carbacycliner. | |
| DK144247B (da) | 16-phenoxy-omega-tetranorprostaglandiner af e-eller f-raekken til anvendelse som fertilitetskontrolmidler | |
| US4004020A (en) | Novel prostanoic acid derivatives and process for the preparation thereof | |
| US4560786A (en) | Δ8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents | |
| US4315013A (en) | Certain pyrrole analogs of prostacyclin derivatives | |
| US5891910A (en) | 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents | |
| EP0213129B1 (de) | Neue 9-halogen-prostaglandine | |
| CA1223871A (en) | 9-bromoprostaglandin derivatives, process for the preparation thereof, and use thereof as medicaments | |
| NO821180L (no) | Fremgangsmaate ved fremstilling av nye prostaglandin- og prostacyclinderivater. | |
| DE3724189A1 (de) | 9-halogen-(z)-(delta)(pfeil hoch)4(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel | |
| DK160759B (da) | Analogifremgangsmaade til fremstilling af carbacyklinderivater | |
| DE3724190A1 (de) | 9-halogen-3-oxa-(z)-(delta)(pfeil hoch)5(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |